Notable HCPCS Code Changes for Medicare Billing

on Wednesday, 29 May 2013. All News Items | Coding | Billing

Transmittal R2704CP details changes to the Medicare Integrated Outpatient Code Editor (I/OCE) that are effective for July 1, 2013. Notable changes that could affect a large number of providers are the changes in covered HCPCS codes for Zoledronic Acid (Reclast and Zometa) and Doxorubicin injection.

The new codes for Medicare are:

HCPCS Code

Description

SI

APC

Q2050

Doxorubicin inj 10mg

K

07046

Q2051

Zoledronic acid 1mg

K

01356

 

 

The current HCPCS codes listed below will not be accepted by Medicare for payment after June 30, 2013. These codes are not being deleted. You will continue to report these codes to non-Medicare payers.

  • J3487, injection, zoledronic acid (Zometa), 1 mg
  • J3488, injection, zoledronic acid (Reclast), 1 mg
  • J9002, injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg

 

Article by Debbie Rubio

Debbie Rubio, BS, MT (ASCP), is the Manager of Regulatory Affairs and Compliance at Medical Management Plus, Inc. Debbie has over twenty-seven years of experience in healthcare including nine years as the Clinical Compliance Coordinator at a large multi-facility health system. In her current position, Debbie monitors, interprets and communicates current and upcoming regulatory and compliance issues as they relate to specific entities concerning Medicare and other payers. You may contact Debbie at  This email address is being protected from spambots. You need JavaScript enabled to view it. .

 

green-iconWe are an environmentally conscious company, dedicated to living “green” both at work and as individuals.

Location

home-icon
1900 Twentieth Avenue South
Suite 220
Birmingham, AL 35209

Connect

phone
205-941-1105
phone
800-592-9639
email
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 mhms